register

News & Trends - Pharmaceuticals

Grant call open for research on chronic fatigue syndrome

Health Industry Hub | October 23, 2019 |

The Morrison Government is calling for proposals for $3 million in research to better understand the causes and improve diagnosis of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS).

Today’s opening of the National Health and Medical Research Council (NHMRC) competitive Targeted Call for Research (TCR) is designed to help stimulate quality collaborative research in this area.

ME/CFS is a complex condition that leaves patients with persistent disabling fatigue, particularly after general activity. Other symptoms that range from mild to severe include muscle and joint pain, as well as headaches. Little is known about its causes, which makes diagnosis and treatment difficult.

This TCR enables Australian researchers to identify approaches that may assist patients presenting with ME/CFS symptoms to be accurately diagnosed and treated.

It will also provide the opportunity to develop a scientifically valid, evidence-based understanding of the pathophysiology and causes of ME/CFS and its impacts.

This TCR is in addition to the Government’s announcement on 20 September 2019 of funding for a health economics study of the impacts and costs associated with ME/CFS, funded through the Medical Research Future Fund’s Targeted Health System and Community Organisation Research Program.

Applications for funding will be open from 23 October 2019 to 29 January 2020.

More information, including the grant opportunity guidelines, will be available on www.grants.gov.au.

You may also like Pharmacist prescribing on the way


News & Trends - Pharmaceuticals

Federal court dismisses Arrotex dispute against Health Minister

Federal court dismisses Arrotex dispute against Health Minister

Health Industry Hub | July 12, 2024 |

Pharma News: The Federal Court has ruled against Arrotex Pharmaceuticals in their bid to challenge the Minister for Health and […]

More


News & Trends - Pharmaceuticals

Largest diabetes study reveals major benefits of dual therapy with SGLT2 inhibitors and GLP1 receptor agonists

Largest diabetes study reveals major benefits of SGLT2 inhibitors and GLP1 receptor agonists dual therapy

Health Industry Hub | July 12, 2024 |

Pharma News: Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to […]

More


News & Trends - Pharmaceuticals

Queensland opens first regional CAR T-cell treatment centre

Queensland launches first regional CAR T-cell treatment centre

Health Industry Hub | July 12, 2024 |

Pharma News: Gilead Sciences and Lymphoma Australia have welcomed the opening of Australia’s first regional CAR T-cell treatment centre at […]

More


News & Trends - Pharmaceuticals

Government inaction leaves essential medicine shortages unresolved

Government inaction leaves essential medicine shortages unresolved

Health Industry Hub | July 12, 2024 |

Pharma News: Over the past 12 months, at least six essential medications and products have been withdrawn from the Australian […]

More


This content is copyright protected. Please subscribe to gain access.